City

Clinical trials near Nanjing, China

Active studies with a listed research site in Nanjing, China.

50active studies

25recruiting now

17countries represented

193largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

Overweight, ObesityCondition

Eloralintide, PlaceboTreatment

Argentina, China157 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07282600See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

Urinary Incontinence,StressCondition

Orforglipron, PlaceboTreatment

Canada, China136 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07202884See eligibility →

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Sleep Apnea, Obstructive, ObesityCondition

Eloralintide, PlaceboTreatment

Australia, Brazil115 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07369011See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

OsteoarthritisCondition

Orforglipron, PlaceboTreatment

Canada, China88 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07153471See eligibility →

Recruiting nowPhase 2

A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight

Obesity, OverweightCondition

BI 3034701, Placebo matching BI 3034701Treatment

Australia, Canada54 locations

Boehringer IngelheimSponsor

Updated 2026-09-03 · NCT07662122See eligibility →

Recruiting nowPhase 3

Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)

Dementia, Mild, Mild Cognitive ImpairmentCondition

Mazdutide, PlaceboTreatment

China8 locations

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolSponsor

Updated 2026-09-02 · NCT07083154See eligibility →

Recruiting nowPhase 1

A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/Obesity

Type 2 Diabetes Mellitus Combined With Overweight or ObesityCondition

TQF3250 capsules, TQF3250 placeboTreatment

China12 locations

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Sponsor

Updated 2026-08-28 · NCT07747857See eligibility →

Recruiting nowPhase 3

A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus

Obesity, OverweightCondition

Elecoglipron, PlaceboTreatment

China, Hong Kong49 locations

AstraZenecaSponsor

Updated 2026-08-27 · NCT07775404See eligibility →

Recruiting nowPhase 3

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

Obesity or Overweight, Type 2 Diabetes MellitusCondition

Placebo, EnicepatideTreatment

Argentina, Australia193 locations

Hoffmann-La RocheSponsor

Updated 2026-08-14 · NCT07351058See eligibility →

Recruiting nowPhase 3

A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes

Obesity, OverweightCondition

Enicepatide, PlaceboTreatment

China18 locations

Hoffmann-La RocheSponsor

Updated 2026-08-13 · NCT07670416See eligibility →

Recruiting nowPhase 3

A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects

Chronic Management of Body WeightCondition

HRS9531 Tablet, HRS9531 Tablet PlaceboTreatment

China2 locations

Fujian Shengdi Pharmaceutical Co., Ltd.Sponsor

Updated 2026-08-13 · NCT07670884See eligibility →

Recruiting nowPhase 3

AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

Obesity, OverweightCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Australia, China92 locations

Novo Nordisk A/SSponsor

Updated 2026-08-04 · NCT07571109See eligibility →

Recruiting nowPhase 3

A Study of BGM0504 in Early T2DM With Obesity

Type 2 Diabetes (T2DM)Condition

BGM0504, semaglutideTreatment

China1 locations

BrightGene Bio-Medical Technology Co., Ltd.Sponsor

Updated 2026-08-04 · NCT07743983See eligibility →

Recruiting nowNot applicable

Transcutaneous Auricular Vagus Nerve Stimulation for Poor Weight-Loss Response to Incretin Receptor Agonists

Obesity & OverweightCondition

transcutaneous auricular vagus nerve stimulation, ShamTreatment

China1 locations

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolSponsor

Updated 2026-07-31 · NCT07619989See eligibility →

Recruiting nowPhase 3

AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

Obesity, OverweightCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Australia, China80 locations

Novo Nordisk A/SSponsor

Updated 2026-07-13 · NCT07571005See eligibility →

Recruiting nowNot applicable

Using Single and Combined Nudge Strategies to Promote Healthier Beverage Intake Among College Students

Obesity, Food SelectionCondition

choice architecture, choice architectureTreatment

China1 locations

Nanjing Medical UniversitySponsor

Updated 2026-07-07 · NCT07625969See eligibility →

Recruiting nowNot applicable

Transcutaneous Auricular Vagus Nerve Stimulation for Poor Weight-Loss Response to Lifestyle Intervention

Obesity & OverweightCondition

transcutaneous auricular vagus nerve stimulation, ShamTreatment

China1 locations

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolSponsor

Updated 2026-06-05 · NCT07630597See eligibility →

Recruiting nowPhase 4

Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes

Type 2 Diabetes, Diabetes With Diabetic Autonomic Neuropathy (Diagnosis)Condition

GLP-1 Receptor AgonistsTreatment

China1 locations

The First Affiliated Hospital with Nanjing Medical UniversitySponsor

Updated 2026-04-30 · NCT07558863See eligibility →

Recruiting nowNot applicable

ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management

Obesity, Weight ControlCondition

Mazdutide, Intensive Lifestyle InterventionTreatment

China13 locations

Shanghai Zhongshan HospitalSponsor

Updated 2026-04-08 · NCT07517042See eligibility →

Recruiting nowNot applicable

Food Intake-Related Brain and Metabolic Responses in Obesity

Obesity, Brain FunctionCondition

Glucose Liquid Meal, Fat Liquid MealTreatment

China1 locations

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolSponsor

Updated 2026-02-06 · NCT07392905See eligibility →

Recruiting nowPhase 4

Evaluating Anti-Obesity Medications 6 Months After Metabolic Surgery

Obesity, Weight LossCondition

Efsubaglutide Alfa Injection, Diet and exercise guidelinesTreatment

China1 locations

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolSponsor

Updated 2026-01-27 · NCT07163650See eligibility →

Recruiting nowPhase 2

Phase II Clinical Study of HDM1005 Injection in Obese Adults Without Diabetes Mellitus

ObesityCondition

HDM1005 injection or placeboTreatment

China1 locations

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Sponsor

Updated 2025-09-30 · NCT06886126See eligibility →

Recruiting nowNot applicable

Nasopharyngeal Airway Combined With Nasal High-flow Oxygen Therapy During Painless Gastroscopy in Obesity Patients

Hypoxia, ObesityCondition

NPATreatment

China1 locations

Nanjing First Hospital, Nanjing Medical UniversitySponsor

Updated 2025-07-22 · NCT06966934See eligibility →

Recruiting nowPhase 4

The Ameliorative Effects of GLP-1RA on Diabetic Cardiac Autonomatic Neuropathy

Type 2 Diabetes, Diabetes With Diabetic Autonomic Neuropathy (Diagnosis)Condition

Glucagon-like peptide-1 receptor agonist：SemaglutideTreatment

China1 locations

The First Affiliated Hospital with Nanjing Medical UniversitySponsor

Updated 2024-06-21 · NCT06461377See eligibility →

Recruiting nowPhase 4

Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes

Type 2 Diabetes MellitusCondition

Tirzepatide, Insulin GlargineTreatment

China1 locations

Nanjing First Hospital, Nanjing Medical UniversitySponsor

Updated 2022-09-23 · NCT05553093See eligibility →

Opening soonPhase 3

A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity

Obesity, OverweightCondition

Berobenatide, PlaceboTreatment

China33 locations

PfizerSponsor

Updated 2026-09-04 · NCT07792954See eligibility →

Opening soonPhase 2

Efficacy and Safety of SYH2069 Injection in Obese Participants Without Diabetes.

Overweight or ObesityCondition

SYH2069 Injection, SYH2069 Injection PlaceboTreatment

China1 locations

CSPC Ouyi Pharmaceutical Co., Ltd.Sponsor

Updated 2026-09-04 · NCT07803991See eligibility →

Opening soonPhase 2

A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin

T2DM (Type 2 Diabetes Mellitus)Condition

SYH2069 Injection (group 1), SYH2069 Injection (group 2)Treatment

China1 locations

CSPC Ouyi Pharmaceutical Co., Ltd.Sponsor

Updated 2026-09-01 · NCT07796477See eligibility →

Opening soonPhase 3

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

Overweight, Prediabetic StateCondition

Orforglipron, PlaceboTreatment

Argentina, China179 locations

Eli Lilly and CompanySponsor

Updated 2026-08-31 · NCT07794579See eligibility →

Opening soonPhase 3

A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

China13 locations

Eli Lilly and CompanySponsor

Updated 2026-08-27 · NCT07790861See eligibility →

Opening soonPhase 3

A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus

Obesity or Overweight, Weight-Related ComorbidityCondition

AZD6234, PlaceboTreatment

Argentina, Brazil88 locations

AstraZenecaSponsor

Updated 2026-08-20 · NCT07776509See eligibility →

Opening soonNot applicable

Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity

Severe ObesityCondition

Sleeve gastrectomy plus early mazdutide initiation, Sleeve gastrectomy followed with early mazdutide placebo initationTreatment

China14 locations

Beijing Friendship HospitalSponsor

Updated 2025-08-21 · NCT07135141See eligibility →

Opening soonPhase 3

A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®

ObesityCondition

Semaglutide, SemaglutideTreatment

China14 locations

Hangzhou Jiuyuan Gene Engineering Co. Ltd.,Sponsor

Updated 2024-10-09 · NCT06633783See eligibility →

Invitation onlyNot applicable

Development of Obesity and Bariatric Surgery

ObesityCondition

Intervention not listedTreatment

China1 locations

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolSponsor

Updated 2024-10-23 · NCT03296605See eligibility →

Invitation onlyNot applicable

Clinical Classification and Imaging Markers in Patients of Obesity

Obesity, fMRICondition

Naturalistic observationTreatment

China1 locations

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolSponsor

Updated 2024-10-18 · NCT06649071See eligibility →

Active, not recruitingPhase 3

A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Brazil, China138 locations

Eli Lilly and CompanySponsor

Updated 2026-08-14 · NCT05869903See eligibility →

Active, not recruitingPhase 2

A Study of CS060380 Tablets in Patients With MASH and Obesity

Metabolic Dysfunction-associated Steatohepatitis (MASH), ObesityCondition

semaglutide, CS060380Treatment

China12 locations

Cascade Pharmaceuticals, IncSponsor

Updated 2026-08-10 · NCT07466017See eligibility →

Active, not recruitingPhase 1

A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight

Healthy Volunteers, Overweight or ObesityCondition

RO7795081, PlaceboTreatment

China2 locations

Hoffmann-La RocheSponsor

Updated 2026-08-10 · NCT07499050See eligibility →

Active, not recruitingPhase 3

A Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1)

Overweight , ObesityCondition

Zovaglutide dose 1, Zovaglutide dose 2Treatment

China45 locations

Beijing QL Biopharmaceutical Co.,LtdSponsor

Updated 2026-08-03 · NCT07230119See eligibility →

Active, not recruitingPhase 3

A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Argentina, China80 locations

Eli Lilly and CompanySponsor

Updated 2026-07-31 · NCT06993792See eligibility →

Active, not recruitingPhase 1

A Study of SYH2069 Injection in Healthy Participants

Overweight or Obesity, DiabetesCondition

SYH2069 Injection, PlaceboTreatment

China1 locations

CSPC Ouyi Pharmaceutical Co., Ltd.Sponsor

Updated 2026-07-30 · NCT07736391See eligibility →

Active, not recruitingPhase 1

A Study of SYH2082 Injection in Healthy Participants

Overweight or ObesityCondition

SYH2082 Injection, PlaceboTreatment

China1 locations

CSPC Ouyi Pharmaceutical Co., Ltd.Sponsor

Updated 2026-07-30 · NCT07736404See eligibility →

Active, not recruitingPhase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Argentina, China80 locations

Eli Lilly and CompanySponsor

Updated 2026-07-29 · NCT06972459See eligibility →

Active, not recruitingPhase 2

This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight

Obesity/OverweightCondition

AZD6234, PlaceboTreatment

China3 locations

AstraZenecaSponsor

Updated 2026-07-02 · NCT07017179See eligibility →

Active, not recruitingPhase 2

Efficacy and Safety of ZT006 in Overweight and Obese Participants

Overweight , ObesityCondition

ZT006, Placebo of ZT006Treatment

China12 locations

Beijing QL Biopharmaceutical Co.,LtdSponsor

Updated 2026-06-12 · NCT07230132See eligibility →

Active, not recruitingPhase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Argentina, China80 locations

Eli Lilly and CompanySponsor

Updated 2026-04-20 · NCT06972472See eligibility →

Active, not recruitingPhase 3

A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity

ObesityCondition

HRS9531 injection, Semaglutide InjectionTreatment

China2 locations

Fujian Shengdi Pharmaceutical Co., Ltd.Sponsor

Updated 2026-02-27 · NCT07285902See eligibility →

Active, not recruitingPhase 2, Phase 3

The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT)

Obesity and OverweightCondition

Phase IIb：Efsubaglutide Alfa 5 mg QW, Phase IIb：Efsubaglutide Alfa 10 mg QWTreatment

China41 locations

Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.Sponsor

Updated 2026-01-30 · NCT06921486See eligibility →

Active, not recruitingPhase 1, Phase 2

Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity

ObesityCondition

Tirzepatide, PlaceboTreatment

China1 locations

Innovent Biologics (Suzhou) Co. Ltd.Sponsor

Updated 2025-12-15 · NCT07000955See eligibility →

Active, not recruitingNot applicable

Evaluate the Efficacy and Safety of SASI Compared with RYGB in the Treatment of Obesity and Related Metabolic Diseases

Bariatric SurgeryCondition

SASI, RYGBTreatment

China1 locations

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolSponsor

Updated 2024-09-19 · NCT06598267See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near Nanjing, China

Current studies

Related cities